Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-464-2677
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
OptionableNot Optionable
Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions
What is Immune Pharmaceuticals' stock symbol?
Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."
How were Immune Pharmaceuticals' earnings last quarter?
Immune Pharmaceuticals Inc (NASDAQ:IMNP) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.05. View Immune Pharmaceuticals' Earnings History.
When is Immune Pharmaceuticals' next earnings date?
What price target have analysts set for IMNP?
1 brokerages have issued 12-month target prices for Immune Pharmaceuticals' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Immune Pharmaceuticals' share price to reach $2.00 in the next year. This suggests a possible upside of 37,635.8% from the stock's current price. View Analyst Price Targets for Immune Pharmaceuticals.
What is the consensus analysts' recommendation for Immune Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immune Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Immune Pharmaceuticals.
Has Immune Pharmaceuticals been receiving favorable news coverage?
Media coverage about IMNP stock has been trending positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immune Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Immune Pharmaceuticals' key competitors?
Some companies that are related to Immune Pharmaceuticals include Affymax (AFFY), Skinvisible (SKVI), Argos Therapeutics (ARGS), Biostar Pharmaceuticals (BSPM), FutureWorld (FWDG), Targeted Medical Pharma (TRGM), HST Global (HSTC), Aeolus Pharmaceuticals (AOLS), Spotlight Innovation (STLT), Tetralogic Pharmaceuticals (TLOG), Orexigen Therapeutics (OREXQ), Epirus Biopharmaceuticals (EPRSQ), Poniard Pharmaceuticals (PARD), Inspyr Therapeutics (NSPX) and Tianyin Pharmaceutical (TPIY).
Who are Immune Pharmaceuticals' key executives?
Immune Pharmaceuticals' management team includes the folowing people:
- Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
- Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)
- Mr. Christine J. Petraglia, Director of Investor Relations
- Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
- Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc
How do I buy shares of Immune Pharmaceuticals?
Shares of IMNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Pharmaceuticals' stock price today?
One share of IMNP stock can currently be purchased for approximately $0.0053.
How big of a company is Immune Pharmaceuticals?
Immune Pharmaceuticals has a market capitalization of $261,358.90. Immune Pharmaceuticals employs 7 workers across the globe.
What is Immune Pharmaceuticals' official website?
How can I contact Immune Pharmaceuticals?
Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected]
MarketBeat Community Rating for Immune Pharmaceuticals (NASDAQ IMNP)
MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
